Xvivo Perfusion AB/Skr XVIVO
1D1W1MYTD1Y5YMAX
Capital at risk
About Xvivo Perfusion AB
Xvivo Perfusion AB is a biotechnology company specializing in the development and commercialization of medical devices and systems for organ transplantation. The company's core products include machine perfusion devices and solutions designed to preserve, evaluate, and transport donor organs, with a particular focus on lungs and hearts. Founded in 1998, Xvivo is headquartered in Gothenburg, Sweden, and has established a presence in key markets worldwide. The company's strategic positioning is enhanced by its commitment to improving transplantation outcomes through innovative technologies and research collaborations. Xvivo's expertise in organ preservation and perfusion technology provides competitive strengths in the field of regenerative medicine.
- Ticker
- Skr XVIVO
- Sector
- Health
- Primary listing
- XSTO
- Employees
- 197
- Headquarters
- Mölndal, Sweden
- Website
- www.xvivogroup.com
XVIVO Metrics
BasicAdvanced
kr 7.8B
87.99
kr 2.81
1.46
-
Price and volume
Market cap
kr 7.8B
Beta
1.46
52-week high
kr 314.80
52-week low
kr 160.00
Average daily volume
59K
Financial strength
Current ratio
3.86
Quick ratio
2.653
Long term debt to equity
0.05
Total debt to equity
0.055
Profitability
EBITDA (TTM)
158.26
Gross margin (TTM)
72.27%
Net profit margin (TTM)
9.89%
Operating margin (TTM)
13.15%
Effective tax rate (TTM)
32.65%
Revenue per employee (TTM)
kr 4,540,000
Management effectiveness
Return on assets (TTM)
2.99%
Return on equity (TTM)
4.13%
Valuation
Price to earnings (TTM)
87.987
Price to revenue (TTM)
8.705
Price to book
3.54
Price to tangible book (TTM)
5.1
Price to free cash flow (TTM)
-1,031.362
Free cash flow yield (TTM)
-0.10%
Free cash flow per share (TTM)
-0.24
Growth
Revenue change (TTM)
8.79%
Earnings per share change (TTM)
-19.96%
3-year revenue growth (CAGR)
19.58%
10-year revenue growth (CAGR)
21.54%
3-year earnings per share growth (CAGR)
45.50%
10-year earnings per share growth (CAGR)
24.66%
Bulls say / Bears say
Xvivo reported net sales of SEK 239 million in Q2 2026, representing 36% organic growth year-over-year (Reuters).
EBITDA margin improved to 19% in Q2 2026 from 13% a year earlier, reflecting operational leverage as the business scales (Reuters).
The EVLP hub pilot in the U.S. expanded to three onboarded organ procurement organizations with 45 additional partnerships in the pipeline, bolstering U.S. commercialization efforts (Reuters).
Investor concerns over uncertain timing of CE mark approval for heart preservation technology in Europe and U.S. FDA PMA submission have weighed on shares (Investing.com).
Gross margins for abdominal products compressed to 55% in Q2 2026 from 68% a year earlier, reflecting cost inefficiencies in the segment (Investing.com).
Services sales declined by 25% year-on-year in Q2 2026, with organ recovery services down 36%, underscoring weakness in the non-device segment (PublicNow).
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2026.
Upcoming events
No upcoming events
Funds containing XVIVO
AllUSDEURGBP
Fund name | Fund size | Skr XVIVO weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.07% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.07% |
iShares Healthcare Innovation£DRDR | £1B | 0.07% |
Xtrackers MSCI Europe Small Cap€DX2J | €3.2B | 0.04% |
Xtrackers MSCI Europe Small Cap£XXSC | £2.8B | 0.04% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.